Tracks walking and jerky movements at home in Huntington's disease
Studies wearable movement sensors to measure walking and chorea in adults with Huntington's disease.
Plain-language title generated from the registry record
Registry title: Digital Measures for Clinical Trial Endpoints in Huntington's Disease
Key facts
- Where
- Rochester, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 65 years old?
Source: NCT07010705, who can take part
Where in United States
- University of Rochester Medical CenterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Rochester
- Trial code
- NCT07010705
- Record updated
- 17 August 2026
- Original description
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.Read full original descriptionShow less
Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives.
Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.
The study may be extended to 3 years to include yearly visits.
Inclusion: Age of 25-65 years; Genetically confirmed HD with CAG >= 40 (HD-ISS Stage 2 or mild/moderate Stage 3); English speaking; Age of 25-65 years; English speaking; Self-identified support person or family member of the enrolled participants with HD; 18 years or older; English speaking.
Exclusion: History of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe; Acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic,; cardiovascular or psychiatric disease; Diagnosis of juvenile-onset HD; Traumatic Brain Injury; Use of an assistive device for ambulation; Montreal Cognitive Assessment (MoCA) score of 18 or lower; Pregnancy; Cannot be enrolled into a blinded intervention trial at Baseline.